Table 1.
The genotypes of the primary cells
| CAF | NTF | |||
|---|---|---|---|---|
| + | - | + | - | |
| MSC requirement | CD90* | CD11B* | CD90* | CD11B* |
| CD44 | CD14* | CD44 | CD14* | |
| CD29* | CD19* | CD29* | CD19* | |
| CD13 | CD79* | CD13 | CD79* | |
| CD105* | CD117 | CD105* | CD117 | |
| CD166 | CD34* | CD166 | CD34* | |
| CD45* | CD45* | |||
| Mesenchymal marker | ACTA2 | ACTA2 | ||
| VIM | VIM | |||
| Pluripotency markers | OCT4 | OCT4 | ||
| SOX2 | SOX2 | |||
| Reference | 18S | 18S | ||
| ACTB | ACTB | |||
The mRNA analysis by RT-PCR of consensus markers of MSC, mesenchymal activation, and pluripotency factors. + = positive expression, − = negative expression. *The reference standard based on the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy [14].